CelularityCELU
Market Cap: $61.3M
About: Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
Employees: 120
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
162% more call options, than puts
Call options by funds: $220K | Put options by funds: $84K
0.41% more ownership
Funds ownership: 3.93% [Q1] → 4.34% (+0.41%) [Q2]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
13% less funds holding
Funds holding: 30 [Q1] → 26 (-4) [Q2]
33% less capital invested
Capital invested by funds: $4.43M [Q1] → $2.96M (-$1.47M) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for CELU.
Financial journalist opinion
Based on 3 articles about CELU published over the past 30 days